These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

588 related articles for article (PubMed ID: 18986388)

  • 1. In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor.
    Neri P; Tagliaferri P; Di Martino MT; Calimeri T; Amodio N; Bulotta A; Ventura M; Eramo PO; Viscomi C; Arbitrio M; Rossi M; Caraglia M; Munshi NC; Anderson KC; Tassone P
    Br J Haematol; 2008 Nov; 143(4):520-31. PubMed ID: 18986388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.
    Shabbeer S; Kortenhorst MS; Kachhap S; Galloway N; Rodriguez R; Carducci MA
    Prostate; 2007 Jul; 67(10):1099-110. PubMed ID: 17477369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma.
    Kaiser M; Zavrski I; Sterz J; Jakob C; Fleissner C; Kloetzel PM; Sezer O; Heider U
    Haematologica; 2006 Feb; 91(2):248-51. PubMed ID: 16461312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase inhibitor valproic acid inhibits proliferation and induces apoptosis in KM3 cells via downregulating VEGF receptor.
    Dong XF; Song Q; Li LZ; Zhao CL; Wang LQ
    Neuro Endocrinol Lett; 2007 Dec; 28(6):775-80. PubMed ID: 18063935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
    Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
    Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valproic acid is a selective antiproliferative agent in estrogen-sensitive breast cancer cells.
    Fortunati N; Bertino S; Costantino L; Bosco O; Vercellinatto I; Catalano MG; Boccuzzi G
    Cancer Lett; 2008 Feb; 259(2):156-64. PubMed ID: 18006146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro.
    Kircher B; Schumacher P; Petzer A; Hoflehner E; Haun M; Wolf AM; Nachbaur D; Gastl G
    Eur J Haematol; 2009 Jul; 83(1):48-56. PubMed ID: 19226363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase inhibitors trichostatin A and valproic acid induce cell cycle arrest and p21 expression in immortalized human endometrial stromal cells.
    Wu Y; Guo SW
    Eur J Obstet Gynecol Reprod Biol; 2008 Apr; 137(2):198-203. PubMed ID: 17376583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells.
    Rocchi P; Tonelli R; Camerin C; Purgato S; Fronza R; Bianucci F; Guerra F; Pession A; Ferreri AM
    Oncol Rep; 2005 Jun; 13(6):1139-44. PubMed ID: 15870934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic administration of valproic acid inhibits PC3 cell growth by suppressing tumor angiogenesis in vivo.
    Gao D; Xia Q; Lv J; Zhang H
    Int J Urol; 2007 Sep; 14(9):838-45. PubMed ID: 17760752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells.
    Raje N; Kumar S; Hideshima T; Ishitsuka K; Yasui H; Chhetri S; Vallet S; Vonescu E; Shiraishi N; Kiziltepe T; Elford HL; Munshi NC; Anderson KC
    Br J Haematol; 2006 Oct; 135(1):52-61. PubMed ID: 16925573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response.
    Lagneaux L; Gillet N; Stamatopoulos B; Delforge A; Dejeneffe M; Massy M; Meuleman N; Kentos A; Martiat P; Willems L; Bron D
    Exp Hematol; 2007 Oct; 35(10):1527-37. PubMed ID: 17697742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy.
    Hubaux R; Vandermeers F; Crisanti MC; Kapoor V; Burny A; Mascaux C; Albelda SM; Willems L
    Eur J Cancer; 2010 Jun; 46(9):1724-34. PubMed ID: 20451370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.
    Daud AI; Dawson J; DeConti RC; Bicaku E; Marchion D; Bastien S; Hausheer FA; Lush R; Neuger A; Sullivan DM; Munster PN
    Clin Cancer Res; 2009 Apr; 15(7):2479-87. PubMed ID: 19318485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis.
    Takai N; Kawamata N; Gui D; Said JW; Miyakawa I; Koeffler HP
    Cancer; 2004 Dec; 101(12):2760-70. PubMed ID: 15536623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of osteogenic differentiation of human mesenchymal stem cells by histone deacetylase inhibitors.
    Cho HH; Park HT; Kim YJ; Bae YC; Suh KT; Jung JS
    J Cell Biochem; 2005 Oct; 96(3):533-42. PubMed ID: 16088945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisome proliferator-activated receptor gamma agonists potentiate the cytotoxic effect of valproic acid in multiple myeloma cells.
    Aouali N; Palissot V; El-Khoury V; Moussay E; Janji B; Pierson S; Brons NH; Kellner L; Bosseler M; Van Moer K; Berchem G
    Br J Haematol; 2009 Dec; 147(5):662-71. PubMed ID: 19793255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valproic acid exhibits biphasic effects on apoptotic cell death of activated lymphocytes through differential modulation of multiple signaling pathways.
    Chen Q; Ouyang DY; Geng M; Xu LH; Zhang YT; Wang FP; He XH
    J Immunotoxicol; 2011; 8(3):210-8. PubMed ID: 21457087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
    Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
    Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valproic acid inhibits the growth of cervical cancer both in vitro and in vivo.
    Sami S; Höti N; Xu HM; Shen Z; Huang X
    J Biochem; 2008 Sep; 144(3):357-62. PubMed ID: 18515856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.